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Proton magnetic resonance spectroscopy
Tensor-based morphometry
Nadir CD4+Cognitive impairment and brain injury are common in people with HIV/AIDS, even when viral replication is
effectively suppressed with combined antiretroviral therapies (cART). Metabolic and structural abnormalities
may promote cognitive decline, but we know little about how these measures relate in people on stable cART.
Here we used tensor-based morphometry (TBM) to reveal the 3D proﬁle of regional brain volume variations in
210 HIV+ patients scanned with whole-brain MRI at 1.5 T (mean age: 48.6 ± 8.4 years; all receiving cART).
We identiﬁed brain regions where the degree of atrophy was related to HIV clinical measures and cerebral
metabolite levels assessed with magnetic resonance spectroscopy (MRS). Regional brain volume reduction was
linked to lower nadir CD4+ count, with a 1–2% white matter volume reduction for each 25-point reduction in
nadir CD4+. Even so, brain volume measured by TBM showed no detectable association with current CD4+
count, AIDS Dementia Complex (ADC) stage, HIV RNA load in plasma or cerebrospinal ﬂuid (CSF), duration
of HIV infection, antiretroviral CNS penetration-effectiveness (CPE) scores, or years on cART, after controlling
for demographic factors, and for multiple comparisons. Elevated glutamate and glutamine (Glx) and
lower N-acetylaspartate (NAA) in the frontal white matter, basal ganglia, and mid frontal cortex—were as-
sociated with lower white matter, putamen and thalamus volumes, and ventricular and CSF space expan-
sion. Reductions in brain volumes in the setting of chronic and stable disease are strongly linked to a
history of immunosuppression, suggesting that delays in initiating cART may result in imminent and irre-
versible brain damage.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. Laboratory of Neuro Imaging,
ce Research Building 225E, 635
el.: +1 310 206 2101; fax: +1
son).
.Open access under CC BY-NC-ND licens1. Introduction
Since the introduction of combined antiretroviral therapies (cART),
opportunistic infections and HIV-associated dementia are much less
common, resulting in marked improvements in life expectancy and
quality of life for people living with HIV (Antinori et al., 2007; Palella
et al., 1998; Schouten et al., 2011). Even so, the incidence of mild to
moderate cognitive dysfunction is increasing in HIV+ cohorts (Ancese. 
133X. Hua et al. / NeuroImage: Clinical 3 (2013) 132–142and Ellis, 2007; Heaton et al., 2010, 2011). 15–50% of patients who have
received long-term treatment showsome cognitive impairment (Cysique
et al., 2004; Simioni et al., 2010), suggesting continued central nervous
system (CNS) involvement despite viral suppression and immune
reconstitution.
Neuroimaging studies have provided useful insights into the pattern
and extent of CNS damage associatedwith HIV infection (Jernigan et al.,
1993; Tucker et al., 2004). The HIV Neuroimaging Consortium (HIVNC)
was formed in 2005 to map the course of structural brain injury over
time, and to relate brain changes to cognitive impairment in a prospec-
tive cohort of HIV+ subjects with a history of chronic disease on stable
cART. Multimodal neuroimaging data was collected to assess the HIV+
brain in terms of: (1) cellular injury and inﬂammatory response mea-
sured by proton magnetic resonance spectroscopy (1H-MRS) (Cohen
et al., 2010a; Harezlak et al., 2011), and (2) structural brain atrophy
measured from standard anatomical magnetic resonance imaging (MRI)
(Cohen et al., 2010a, 2010b).
To date, neuroimaging studies of HIV+ populations have found
important associations between CNS structural abnormalities, immuno-
logical markers, and neural injury reﬂected by brain metabolite disrup-
tion. Reduced cortical and subcortical volumes in addition tometabolite
abnormalities persist in HIV patients receiving cART, and are associated
with advanced disease stage and cognitive impairment (Chiang et al.,
2007; Cohen et al., 2010a, 2010b; Harezlak et al., 2011; Patel et al.,
2003; Paul et al., 2002, 2008; Tate et al., 2009, 2011). Among structural
brain abnormalities, atrophy in the basal ganglia and frontal white mat-
ter, as well as abnormalities in periventricular white matter are most
commonly observed, suggesting a primary involvement of the frontal–
striatal networks (Dal Pan et al., 1992; Navia et al., 1986a; Tate et al.,
2009). White matter atrophy is common in both pre- and post-cART
HIV+ cohorts and is strongly associated with disturbances in cognitive
function (Gongvatana et al., 2009; Navia et al., 1986a; Schouten et al.,
2011). Abnormalities previously reported in the basal ganglia structures
include either hypertrophy (an increase in volume) (Castelo et al.,
2007) or hypotrophy (a deﬁcit in volume) (Jernigan et al., 2005) in
HIV+ patients, possibly due to the different stages of infection and re-
sponse to treatment. Methamphetamine use may also cause hypertro-
phy of the white matter (perhaps due to inﬂammation); although the
cause and consistency of the white matter effects of meth are not
well-understood, some cohorts deliberately assess HIV participants
with co-morbid IV drug use, where the balance of effects tends to reﬂect
a combination of viral effects and those of chronic drug use. Recent
evidence for white matter changes in HIV+ participants includes faster
rates of white matter volume loss in HIV+ patients on stable cARTwith
viral suppression (Cardenas et al., 2009), lower white matter fractional
anisotropy as well as greater brain network deﬁcits measured by diffu-
sion tensor imaging (Chen et al., 2009; Jahanshad et al., 2012; Nir et al.,
2013; Pfefferbaum et al., 2007; Pfefferbaum et al., 2009; Ragin et al.,
2004; Tate et al., 2010; Wu et al., 2006). In the HIVNC cohort and a sep-
arate cohort named CNS HIV Antiretroviral Therapy Effects Research
(CHARTER), nadir CD4+ count has been associated with lower total
white matter and subcortical gray matter volumes (Cohen et al.,
2010b; Jernigan et al., 2011), as well as lower corpus callosum volumes
(Tate et al., 2011).
Brain MRS shows regional metabolite disturbances, including in-
creases in choline and myoinistol, along with decreases in N-acetyl
aspartate, reﬂecting inﬂammation and neuronal injury, respectively, in
the frontal white matter and subcortical nuclei (Chang et al., 2004;
Harezlak et al., 2011; Sacktor et al., 2005; Yiannoutsos et al., 2004). A re-
cent HIVNC study of 240 HIV+ patients showed a persistence of these
abnormalities in the setting of stable disease and cART (Harezlak et al.,
2011). Although cerebral metabolite abnormalities were associated
with cortical and subcortical gray matter deﬁcits in the HIVNC cohort,
signiﬁcant relationships with white matter volume have not yet been
detected (Cohen et al., 2010a). Here we set out to use a sensitive MRI
analysis technique called tensor-based morphometry (TBM) to relateclinical markers of HIV infection and brain metabolites to differences
in regional brain volume. TBM is a nonlinear registration based ap-
proach designed to detect regional differences in brain volume in a
cohort, and study factors that affect them (Chiang et al., 2007; Chung
et al., 2001; Davatzikos, 1996; Fox et al., 2001; Hua et al., 2013; Shen
and Davatzikos, 2003; Studholme et al., 2001; Thompson et al., 2000).
Multivariate TBM has been recently applied to study structural abnor-
malities (Lepore et al., 2008) and lateral ventricular surface differences
(Wang et al., 2010) associated with HIV/AIDS. Unlike traditional ROI-
based volumetric methods, TBM provides a whole brain voxel-based
analysis without requiring any prior anatomical hypothesis about where
differences should be found. It is a helpful method to study the proﬁle
of white matter atrophy on anatomical MRI, which lacks detectable
anatomical landmarks to parcellate white matter in a consistent way.
Here wemapped the 3D pattern of brain abnormalities in a large co-
hort of HIV-infected patients on stable cART, as part of the HIVNC study.
Regional brain volume variations in 210 HIV-infected patients – both
cognitively asymptomatic and symptomatic – were examined for rela-
tionships with MRS cerebral metabolite levels and HIV clinical indices
such as nadir and current CD4+ levels, HIV RNA concentrations and
duration of known HIV infection. We hypothesized that the level of
atrophy in frontal brain regions, particularly the white matter, and the
basal ganglia, would relate to metabolic markers of neuronal injury,
and to nadir CD4+ count, a marker of immune function and a major
risk factor for neurocognitive impairment (Heaton et al., 2011).
2. Materials and methods
2.1. Subjects
We studied 210 HIV-infected patients (mean age 48.6 ± 8.4 years;
175 men and 35 women) enrolled in the HIVNC during the years
2003–2009. Subjects were recruited from seven sites across the
United States including Colorado (N = 36), UCLA (N = 42), UCLA-
Harbor (N = 54), UCSD (N = 11), Rochester (N = 49), Stanford
(N = 15), and Pittsburgh (N = 3). Subjects of various ethnicities
were enrolled, including Caucasians (N = 148; 70% of the cohort),
African-Americans (N = 54; 26%), Asians (N = 2; 1%) and Native
Americans and American Indians (N = 6; 3%). Inclusion criteria includ-
ed nadir CD4+ cell count less than 200 cells/mm3; stable antiretroviral
regimenwith any Food and Drug Administration (FDA)-approved ther-
apy for at least 12 consecutive weeks prior to the study; hemoglobin
greater than 9.0 g/dl; serum creatinine less than three times the upper
limit of normal (ULN); aspartate aminotransferase (serum glutamic-
oxaloacetic transaminase) [AST (SGOT)], alanine transaminase (serum
glutamic–pyruvic transaminase) [ALT (SGPT)], and alkaline phospha-
tase of three times the ULN or less.
Exclusion criteria included severe premorbid or comorbid psychiat-
ric disorders, confoundingneurologic disorders such as chronic seizures,
stroke, head trauma resulting in loss of consciousness of more than
30 min, multiple sclerosis, brain infection (except for HIV), or brain
neoplasms, including CNS lymphoma and active alcohol and drug
abuse or related medical complications within 6 months of study. All
procedures were reviewed and approved by local institutional review
boards (IRBs). All participants gave written informed consent.
2.2. Clinical characteristics
Clinical measures included the AIDS Dementia Complex (ADC) stage
(Navia et al., 1986a, 1986b; Price and Brew, 1988), current CD4+
counts, nadir CD4+ counts (lowest cell counts prior to treatment),
HIV RNA viral load in plasma and cerebrospinal ﬂuid (CSF), duration
of HIV infection or duration of known infection when patient was ﬁrst
tested, antiretroviral CNS penetration-effectiveness (CPE) scores, and
years on cART. Although 210 participants were available for study,
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(Table 1, Total N).
Global cognitive status was assessed using ADC staging, as previous-
ly described (Price and Brew, 1988). ADC staging is strongly correlated
with the severity of brain pathology (Navia et al., 1986b), immunopa-
thology (Brew et al., 1995) and abnormal brain metabolites (Chang
et al., 1999) and provides a robust measure of cognitive function in
HIV+ patients. ADC staging was performed by a trained clinician at
each site based on the neurological examination, assessment of func-
tional impairment, and neuropsychological performance, as previously
described (Price et al., 1990). Neuropsychological impairment was
deﬁned as performance at least 1.0 standard deviation below normative
values on two or more neuropsychological tests, or at least 2.0 standard
deviations below normative values on one or more tests. Participants
were classiﬁed as stage 0 (normal), 0.5 (subclinical), 1 (mild), 2 (mod-
erate), 3 (severe), or 4 (end stage). In our study, 200 patients had ADC
staging measures and no patients were at ADC stage 3 or 4 (Table 1).
To summarize effects at different stages, we also converted the original
ADC stage into a binary version (i.e., the “binary ADC stage”), with ADC
stages 0 and 0.5 coded as “0” and ADC stages 1 and 2 coded as “1”.
CD4+ counts and HIV RNA viral load were measured from each
patient's blood sample (plasma) and CSF, using standardized methods
(e.g., Roche Amplicor techniques) (Mulder et al., 1994). Pre-treatment
CD4+ count or nadir CD4+ count is the most well known risk factor
for, and predictor of, treatment outcomes and neurocognitive impair-
ment in HIV infection (Schouten et al., 2011). It reﬂects the lowest mea-
sured cell count during the course of infection, indicating the severity of
immunosuppression prior to the initiation antiretroviral therapy. The
record of nadir CD4+ was obtained from the patient's medical history.
Duration of HIV known infection (in years) was estimated as the time
difference between the date of diagnosis of HIV seropositivity from
the date of the image acquisition, and it should be understood that
this does not necessarily reﬂect true duration of infection. The CPE scor-
ing was based on the ﬁrst proposal of Scott Letendre and colleagues
(Letendre et al., 2009). CPE scores range from 0 to 4, with 87% of obser-
vations between 0.5 and 2.5.
2.3. Structural magnetic resonance imaging (MRI)
Each participant underwent a MRI scan using a 1.5 T scanner
manufactured by GEHealthcare or Siemens Healthcare. GE scans follow-
ed a standardized structural imaging protocol that included a spoiled
gradient-recalled echo (SPGR) T1-weighted volumetric scan with theTable 1
Clinical characteristics of the study participants. Cognitive impairment was evaluated in
200 subjects, using AIDS dementia complex (ADC) scores. Median and interquartile
range (IQR) are listed for continuous variables. Stages were coded as: ADC stage-0, not
impaired; stage-0.5, having subclinical impairment; stage-1, mildly impaired; stage-2,
moderately impaired. Plasma HIV RNA was deﬁned as undetectable when the viral load
is b=400 copies/mL. CSF HIV RNA was deﬁned as undetectable when the viral load is
b=75 copies/mL.
Continuous variables Total N Median IQR
Nadir CD4+ (cells/mm3) 210 37 [13–91.75]
CD4+ (cells/mm3) 204 328 [214–474]
Duration of HIV (years) 210 12 [8–18]
CPE score 198 1.5 [1–2]
Years on cART 177 1.6 [0.7–3.3]
Categorical variables Total N Categories n (%) Binary
ADC stage 200 Stage-0 122 (61%) 0
Stage-0.5 51 (25%) 0
Stage-1 24 (12%) 1
Stage-2 3 (2%) 1
Plasma HIV RNA 202 Undetectable 170 (84%) 1
Detectable 32 (16%) 0
CSF HIV RNA 60 Undetectable 43 (72%) 1
Detectable 17 (28%) 0following parameters: repetition time (TR) ranged from 20 to 22 ms;
echo time (TE) ranged from 5 to 7 ms; ﬁeld-of-view (FOV) = 20 cm;
slice thickness = 1.3 mm; ﬂip angle = 30°; matrix size = 256 × 128,
with the number of excitations (NEX) set to 1. Siemens scans were
performed on Sonata or Symphony models. Fourteen percent of the
total scans (N = 29) were acquired on Siemens scanners. For scans
performed with Siemens scanners we used a structural imaging pulse
sequence and parameters matched to the protocol used on GE scanners
(TR/TE of 20/10.1 ms; FOV = 22 cm; slice thickness = 1.3 mm; ﬂip
angle = 30°; matrix size = 256 × 192; NEX set to 1). Reliability and
validity tests were conducted by imaging ﬁve subjects using the GE
and Siemens scanners on the same day. Volumetric measures of a
group of brain structures were made using FreeSurfer software on the
10 structural images from these ﬁve subjects. Volume differences attrib-
utable to scanner type were less than 5%. Accordingly, we did not per-
form separate TBM analyses for scans acquired with GE and Siemens
scanners. Furthermore the small fraction of the scans donewith Siemens
scanners (14%)made it unlikely that any valid conclusions about scanner
type bias could be drawn. But more importantly, there were no statisti-
cally signiﬁcant differences in age, sex, or ethnicity (all p-values N 0.05)
between the groups of subjects scanned on each scanner.
2.4. Proton magnetic resonance spectroscopy (1H-MRS)
The 1H-MRS protocol has been previously described (Cohen et al.,
2010a; Harezlak et al., 2011). Brieﬂy, levels of cerebral metabolites
N-acetylaspartate (NAA), myo-inositol (MI), choline-containing com-
pounds (Cho), glutamate/glutamine (Glx), and creatine (Cr) were
measured by single-voxel 1H spectra using a PRESS pulse sequence.
Voxels 6 ml were prescribed in three regions: gray matter in mid-
frontal cortex (MFC), right or left mid-frontal white matter in centrum
semiovale (FWM), and right or left deep gray matter in basal ganglia
(BG). Field homogeneity and water suppression were adjusted using
automated algorithms provided by the manufacturer. Water-
suppressed spectra were collected with echo time/repetition time
(TE/TR) of 35/3000 ms, bandwidth 2500 Hz, 128 averages. MRS data
were acquired using matched pulse sequence parameters on GE and
Siemens MRI units. In addition to the water-suppressed MRS acquisi-
tion, single-scan fully relaxed unsuppressed water FIDs were acquired
from each voxel at seven different echo times (TE = 30, 45, 65, 100,
200, 500, and 1500 ms; TR = 15 s). These data were used to infer the
voxel's CSF content which was used in the metabolite concentration
computations. To control for a possible instrument bias, we collected
phantom MRS data concurrently with the subject evaluation, using
the same protocol described above.
The time domain spectral data were transferred to a central MRS
processing site, at the John A. Burns School of Medicine, University of
Hawaii (site PI: Thomas Ernst). MR spectra were evaluated for quality
based on visual inspection and the %SD (Cramer–Rao lower bounds)
and FWHM outputs from the LC Model spectral analysis software
(Provencher, 2001). Concentrations of metabolites NAA, MI, Cho, Glx
and Cr were computed using LC Model with unsuppressed water FID
at TE = 35 ms used for eddy-current correction. The MRS signals pro-
duced by glutamine and glutamate overlap almost completely in 1.5 T
human brain spectra. This introduces a confound into the LCModel sig-
nal quantiﬁcation algorithm,which leads to incorrect assignment of glu-
tamate signal to glutamine and vice versa. Accordingly, as has been
customary for LCModel processing of 1.5 T brain spectra for many
years, we report only the sum of the glutamate and glutamine concen-
trations (Glx) in this work. Both absolute concentration and metabo-
lite/Cr ratio were computed for each metabolite and used in our
analyses. This automated processing method yields metabolite concen-
tration estimates with coefﬁcient of variation b15% (Lee et al., 2003).
The variability in measurements of metabolite ratios over the group of
human subjects was about 3-fold larger than the variability measured
in the phantoms. The variability in the phantom metabolite ratio
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mean, withmost of the variation fallingwithin 2–3%. Because the phan-
tom agreement between sites (including between acquisitions) that
used Siemens and GE scanners was within a few percent, we did not
make scanner-speciﬁc corrections to the derived metabolite concentra-
tions and ratios.2.5. Missing values
The Data Coordinating Center at the Indiana University School of
Medicine followed strict data collection procedures that were put in
place in the HIVNC study protocol. Most data were available for all
210 patients reported in this manuscript. However, missing entries are
unavoidable in a large multi-site study. MRS data for most regions and
metabolites had between 3.8% and 7.1% valuesmissing. The only excep-
tions are metabolites in the basal ganglia, where 11.4% to 13.8% values
were missing, and Glx values in all brain regions where about 90% of
the region-speciﬁc values are collected. The reasons for missing data
are two-fold: ﬁrst, the subcortical location of the basal ganglia voxel is
especially susceptible to CSF interference resulting in poor metabolite
estimates; second, Glx concentrations are harder to estimate than the
other four metabolites. The metabolite concentrations were quantiﬁed
using the package LC Model (Provencher, 1993). The ﬁtting results are
given both as absolute concentrations and as ratios to the total Cr
Level. The estimated concentrations were used in further analysis only
when the metabolite concentration was estimated with the Cramer–
Rao lower bound (CRLB) ≤20%. In other words, the MRS data were ac-
quired for all subjects, except for a small number which were excluded
for quality and technical reasons. Using a 1.5 T magnetic ﬁeld strength,
fourmetabolites (NAA, Cr, Cho,mI) can be estimatedwell formost spec-
tra. However, Glx estimation is harder, and frequently the estimates
were rejected by the CRLB criterion.2.6. Tensor-based morphometry (TBM)
For TBM analysis of the anatomical images, pre-processing steps in-
cluded N3 bias ﬁeld correction (Sled et al., 1998), and automated linear
registration to a target brain template using 12-parameter afﬁne regis-
tration (Collins et al., 1994). Globally aligned images were resampled
with an isotropic matrix of 220 voxels in the x-, y-, and z-dimensions;
each interpolated voxel was 1 mm × 1 mm × 1 mm in size.
Using the registered images, an unbiased group average template,
called a minimal deformation target (MDT), was created to serve as
the target for nonlinear registration. MDT construction is detailed in
prior papers (Hua et al., 2008, 2009).
To quantify 3D patterns of volumetric tissue change, all globally
aligned individual brain images were non-linearly registered to the
MDT, using inverse-consistent elastic intensity-based registration (Leow
et al., 2005). A Jacobian matrix ﬁeld was derived from the gradients
of the deformation ﬁeld that aligned an individual brain to the MDT
template. The determinant of the local Jacobian matrix was derived
from the forward deformation ﬁeld to characterize local volume differ-
ences. Color-coded Jacobian determinants were used to illustrate regions
of volume expansion, i.e. those with det J(r) N 1, or contraction, i.e. det
J(r) b 1, relative to the group template (Ashburner and Friston, 2003;
Chung et al., 2001; Freeborough and Fox, 1998; Riddle et al., 2004;
Thompson et al., 2000; Toga, 1999). As all images were registered to
the same template, these Jacobian maps share a common anatomical
coordinate deﬁned by the MDT. Individual Jacobian maps were retained
for further statistical analyses.
Given the cross-sectional nature of this study and the fact that it
included only HIV positive individuals, the references to “atrophy” are
indirect. Brain atrophy in this manuscript refers to less brain tissue or
greater CSF expansion relative to the average brain template.2.7. Voxel-wise linear regressions
At each voxel in the brain, multiple linear regression was used to
model relationships between structural brain differences (Jacobian
determinant values) and cerebral metabolite levels as well as nadir
CD4+ count, after controlling for age, sex, and ethnicity. Ethnicity (E)
was coded using 2 dummy variables, African Americans were coded as
“1” for E1 only, and “Others” (including Asians, Native Americans and
American Indians) were coded as “1” for E2 only, while Caucasians
were coded as “0” for both E1 and E2. Cerebral metabolite variables in-
cluded absolute levels of NAA,MI, Cho, Glx, andCr, andmetabolite ratios
of NAA/Cr, Cho/Cr, MI/Cr, and Glx/Cr, in MFC, FWM, and BG areas. We
modeled region brain volumes by ﬁtting the following multiple regres-
sion model at each voxel:
Jacobian ¼ β0 þ β1  Ageþ β2  Sexþ β3  E1þ β4  E2
þ β  Covariate of interest þ error
We used this voxel-wise multiple regression to assess whether
the local brain volume differences (regional brain volume differences
relative to the MDT) were signiﬁcantly associated with the covariates
of interest. Statistical or “p-value”mapswere generated to visualize pat-
terns of voxel-wise signiﬁcance. The signiﬁcance maps (uncorrected)
were subsequently corrected for multiple comparisons using the stan-
dard false discovery rate (FDR)method,with the conventionally accept-
ed false-positive rate of 5% (q = 0.05) (Benjamini andHochberg, 1995).
The FDR correction was applied to two-sided tests, inside the whole
brain, without considering the sign of partial regression coefﬁcients
(β-values). The uncorrected maps were thresholded with the FDR criti-
cal P-values; the surviving voxels (or suprathreshold voxels) are ex-
pected to have no more than 5% false positives. In other words, it is
expected that the voxel-by-voxel associations are true associations
at 95% of the suprathreshold voxels shown. The color-coded maps of
β-values, displayed over the MDT, represent areas of signiﬁcant associ-
ation, where the estimated degree of tissue deﬁcit or excess is displayed
at each voxel (as a percentage, relative to the template) that is associat-
ed with brain metabolite or clinical measures, after controlling for age,
sex, ethnicity, and multiple comparisons.
2.8. Evaluating the relative importance of predictors and ranking the overall
effect sizes
To assess the relative importance of predictors in a linear regression
model, we calculated T-statistics on the partial regression coefﬁcients
(β-values) at voxels that passed FDR correction. We provided summaries
ofmean and standarddeviations for both theβ-values and the T-statistics,
separated into two groups showing positive and negative associations.
Due to the high spatial resolution of the voxel-wise association study,
none of the summaries above provides a deﬁnitive measure of impor-
tance of the predictors in amultiple linear regressionmodel. They offer in-
formation about the spatial variability and relative strength of the
statistical associations.
The volume of signiﬁcant voxels that passed the FDR critical P-value
(corrected formultiple comparisons)was used to deﬁne the overall effect
sizes as “areas of signiﬁcance”. The effect sizewasmeasured both in terms
of the number of voxels and as a percentage of the overall brain volume,
which are interchangeable.We note that there is no standardway to rank
the effect size in a statistical map, as it depends onwhether a large differ-
ence in a fewvoxels is consideredgreater than awidespreaddiffuse effect.
3. Results
3.1. Brain atrophy is correlated with cerebral metabolite levels
We set out to ﬁnd which of the available MRS measures best pre-
dicted brain atrophy. After controlling for age, sex, and ethnicity, and
Table 3
Positive associations (i.e., with positive β-values) are shown here between metabolite
levels and brain volumes, listing the effect size as the number of signiﬁcant voxels passing
the FDR critical P-value (and as a percentage of the entire brain). We also report the mean
(standard deviation-SD) of the β-values within the areas declared signiﬁcant, mean (SD)
of the T-statistics, and areas of signiﬁcance.






NAA in FWM 512,139 (27%) 2.2 (0.6) 3.2 (0.5) Whole brain WM
NAA in BG 264,643 (14%) 2.2 (0.5) 3.3 (0.5) Whole brain WM
NAA in MFC 94,268 (5%) 2.1 (0.5) 4.0 (1.0) Thalamus, putamen,
midbrain, medial
orbital gyrus
Glx in BG 375,095 (20%) 1.3 (0.4) 3.3 (0.7) CSF/ventricles
Glx in MFC 34,077 (2%) 1.2 (0.2) 3.8 (0.5) Putamen, midbrain
Cr in MFC 49,123 (3%) 2.5 (0.5) 4.1 (0.7) Thalamus, putamen,
midbrain
Cho in MFC 9478 (1%) 6.7 (0.8) 4.2 (0.5) Putamen, midbrain
MI in MFC 1847 (0.1%) 2.0 (0.3) 4.4 (0.2) Putamen
Ratio
NAA/Cr in BG 43,102 (2%) 11.3 (2.2) 3.4 (0.3) Frontal and parietal
WM
Glx/Cr in BG 267,511 (14%) 6.4 (1.7) 3.2 (0.6) CSF
Glx/Cr in FWM 15 (0.001%) 7.8 (0.4) 3.9 (0.02) CSF
Cho/Cr in FWM 85,985 (5%) 41.3 (7.8) 3.5 (0.4) CSF
MI/Cr in FWM 92,851 (5%) 15.5 (8.2) 3.2 (0.5) CSF/ventricles
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niﬁcantly associated with absolute levels of (1) NAA measured in all
three brain regions of interest (FWM, BG, and MFC), (2) Glx in BG and
MFC, (3) Cr in MFC, (4) Cho in MFC, and (5) MI in MFC (Tables 3
and 4). Disrupted cerebral metabolite levels were linked to greater
brain atrophy, as reﬂected by less brain tissue or greater CSF expansion
relative to the average brain template. Although two-tailed statistical
tests were used, we separated the results into positive (Table 3) and
negative (Table 4) associations to make clear the directions of associa-
tion. The effect sizewas summarized as the number of signiﬁcant voxels
passing the FDR critical P-value, and equivalently, as a percentage of
the whole brain. We also examined the mean and standard deviation
of the partial regression coefﬁcient (β-value), T-statistics, and areas of
signiﬁcance.
In a separate analysis, the relative metabolite concentrations were
calculated with reference to the levels of Cr (Tables 3 and 4). Glx/Cr
and NAA/Cr, measured in the basal ganglia, remained strong predictors
of brain atrophy. Compared to the absolute measures, all relative me-
tabolite concentrations (NAA, Glx, Cho, and MI) measured in the MFC
area and NAA measured in the FWM were no longer associated with
brain volume variations. Additionally, MI/Cr, Cho/Cr, and Glx/Cr mea-
sured in the FWM showed signiﬁcant correlations with regional brain
volumes, while their absolute counterparts did not show a signiﬁcant
association.
When ranking the absolute and relative metabolite analyses to-
gether, the top two metabolites were absolute concentrations of Glx
in BG (positive associations: 375,095 signiﬁcant voxels/20% of the
total brain volume; negative associations: 223,333 voxels/12%; overall:
598,428 voxels/32%) and NAA in FWM (positive associations: 512,139
signiﬁcant voxels/27% of total brain volume; negative associations:
40,448 voxels/2%; overall: 552,587 voxels/29%) (Tables 3 and 4). Partial
regression coefﬁcient maps show the associations between atrophy
proﬁles and metabolite levels for Glx in the BG (Fig. 1) and NAA in theTable 2
Summary of absolute and ratio of MRS metabolite levels inside each region-of-interest
(ROI) in the participant cohort, showing the number of subjects with available data (N),
minimum (Min) and maximum (Max) values, group mean (Average) and standard
deviation (SD).
ROI N Min Max Average SD
Absolute
NAA FWM 202 5.5 11.5 8.2 1.12
BG 186 4.0 10.5 7.9 1.19
MFC 197 2.8 9.0 6.8 1.09
Cr FWM 202 3.2 7.6 4.9 0.63
BG 186 2.1 8.0 5.3 0.84
MFC 197 1.9 7.5 4.7 0.80
Cho FWM 202 0.8 4.4 1.7 0.38
BG 186 0.7 4.5 1.5 0.33
MFC 197 0.4 2.1 1.2 0.28
MI FWM 202 1.3 11.3 5.1 1.13
BG 182 1.2 6.7 4.2 0.86
MFC 196 1.9 8.0 4.4 1.03
Glx FWM 185 3.2 14.7 8.2 1.71
BG 164 4.4 14.8 10.2 2.20
MFC 181 3.5 14.0 9.8 1.72
Ratio
NAA/Cr FWM 202 1.2 2.3 1.7 0.20
BG 184 1.0 2.1 1.5 0.24
MFC 196 1.0 1.9 1.5 0.14
Cho/Cr FWM 202 0.2 0.5 0.3 0.06
BG 184 0.2 0.4 0.3 0.05
MFC 196 0.1 0.4 0.3 0.04
MI/Cr FWM 201 0.5 1.8 1.1 0.21
BG 181 0.3 1.3 0.8 0.18
MFC 195 0.4 1.5 0.9 0.14
Glx/Cr FWM 184 0.7 2.6 1.7 0.32
BG 164 0.8 3.1 1.9 0.38
MFC 181 1.3 3.0 2.1 0.29FWM (Fig. 2). Higher levels of Glx in the BG and lower levels of NAA
in FWM were associated with lower white matter volume and greater
ventricle/CSF expansion; these results are in the hypothesized direction.
Generally, cerebral white matter deﬁcits (lower volumes) were as-
sociated with lower absolute NAA concentrations measured in FWM
and BG as well as NAA/Cr in BG, (2) higher absolute Glx concentrations
in the BG, Glx/Cr in BG, MI/Cr in FWM, Cho/Cr in FWM. Volume deﬁcits
in the deep brain nuclei, such as the putamen, were linked to lower
levels of NAA, Cr, Glx, Cho, and MI measured in the mid-frontal gray
matter, or MFC.
3.2. Brain atrophy linked to nadir CD4+ cell count
Nadir CD4+ cell count represents the history of greatest immuno-
suppression. After controlling for demographic factors and multipleTable 4
Negative associations (negative β-values) between metabolite levels and brain volumes,
listing the effect size as the number of signiﬁcant voxels passing the FDR critical P (and
as a percentage of the entire brain). We also report the mean (standard deviation-SD) of
the β-values within the areas declared signiﬁcant, mean (SD) of the T-statistics, and
areas of signiﬁcance.






NAA in FWM 40,448 (2%) −3.6 (1.5) −3.0/0.4 CSF/ventricles
NAA in BG 56,573 (3%) −3.5 (1.6) −3.3/0.4 CSF/ventricles
NAA in MFC 59,819 (3%) −4.4 (1.8) −3.7/0.5 CSF/ventricles,
cerebellum
Glx in BG 223,333 (12%) −1.3 (0.3) −3.3/0.7 Whole brain WM
Glx in MFC 31,009 (2%) −2.4 (0.9) −3.5/0.3 CSF/ventricle,
cerebellum
Cr in MFC 31,973 (2%) −6.0 (2.2) −3.6/0.4 CSF/ventricles
Cho in MFC 0 0 None
MI in MFC 0 0 None
Ratio
NAA/Cr in BG 52,639 (3%) −17.3 (7.5) −3.4/0.2 CSF
Glx/Cr in BG 255,298 (14%) −7.5 (2.0) −3.4/0.6 Whole brain WM
Glx/Cr in FWM 5622 (0.3%) −12.5 (2.1) −4.2/0.2 Cerebellum
(inferior tonsil area)
Cho/Cr in FWM 6605 (0.4%) −35.7 (7.3) −3.3/0.2 Parietal WM
MI/Cr in FWM 267,932 (14%) −12.5 (3.2) −3.3/0.5 Whole brain WM
Fig. 1. Brain atrophy relates to Glx levels measured in BG. 3Dmaps show regions where the absolute Glx concentrations measured in basal ganglia are signiﬁcantly associated with regional
brain volumes, after controlling for age, sex, ethnicity, and multiple comparisons. Displayed over the MDT, the color-coded regression coefﬁcients, β-values, are shown at each voxel,
representing the estimateddegree of tissue deﬁcit or excess at each voxel (as a percentage, relative to the template) that is associatedwith theGlx concentrationsmeasured inBG.Multiple
comparisons across voxels are corrected with a regional FDR method; only voxels that survive this statistical correction are shown in color.
Fig. 2. Brain atrophy relates to NAA levels measured in FWM. Here we show brain regions where the absolute NAA concentrations measured in frontal white matter are signiﬁcantly asso-
ciatedwith regional brain volumes, after controlling for age, sex, ethnicity, andmultiple comparisons. Displayed over theMDT, the color-coded regression coefﬁcients, β-values, are shown
at each voxel, representing the estimated degree of tissue deﬁcit or excess at each voxel (as a percentage, relative to the template) that is associatedwith NAA concentrations (in absolute
units). Multiple comparisons across voxels are corrected with a regional FDR method; only voxels that survive this statistical correction are shown in color.
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of brain atrophy (Fig. 3). Lower nadir CD4+ count was associated
with greater atrophy (positive β-values in Fig. 3), in a broad region
encompassing frontal and parietal white matter bilaterally, and the
cerebellum. For every 25-point reduction in nadir CD4+ cell count,
there was a 1–2% greater volume deﬁcit, on average, in regional white
matter volumes (regression coefﬁcients β ranged from 0.04 to 0.08%).
CSF volume showed a negative correlation with nadir CD4+ counts —
as expected, since CSF spaces expandwhen adjacent tissue is atrophied.
The other clinical measures, including current CD4+ count, ADC stage,
HIV RNA concentration in plasma or CSF, duration of HIV infection, CPE
scores, and years on cART,were not signiﬁcantly related to brain volume
after controlling for demographic factors, and correcting for multiple
comparisons.Fig. 3. Brain atrophy relates to nadir CD4+ counts. In people with lower nadir CD4+ counts, br
(blue colors denote a positive correlation, with lower volumes in people with low CD4+ counts). I
volume, the regression coefﬁcients, β, are shown at each voxel. Results shown are corrected for
the estimateddegree of tissue deﬁcit – or enlargement, for CSF spaces – at eachvoxel (in percent
for age, sex, and ethnicity. For each 25-point reduction in nadir CD4+, there was, on average,
to 0.08%, so 25 times this amounts to a 1–2% volume deﬁcit relative to the template).3.3. Ranking of overall effect sizes
As predictors of atrophy, we ranked absolute and relative metabo-
lites as well as nadir CD4+, to compare the strengths of their statistical
associations with brain atrophy (Fig. 4). As deﬁned in the methods, a
larger effect size generally denotes a more widespread effect on the
brain, while a smaller effect size is typically regional, or detected in a
more restricted pattern. Nadir CD4+ demonstrated the highest effect
size as a predictor of brain atrophy, with 35% of the total brain volume
showing signiﬁcant correlations with nadir CD+ counts. Absolutemea-
sures of metabolites generally showed higher effect sizes compared to
their ratios (metabolite/Cr). Among the absolute metabolite measures,
Glx in BG and NAA in FWM demonstrated the strongest associations
with volume deﬁcits throughout the brain. The top two associationsain atrophy is greater in a broad region that encompasses much of the deep white matter
n brain regions where nadir CD4+ counts are signiﬁcantly associated with white matter
multiple comparisons, by thresholding them at the critical p-value. The β-values represent
age relative to the template) that is associatedwith thenadir CD4+count, after controlling
a 1–2% greater deﬁcit in white matter volume (in blue regions: β-values range from 0.04
Fig. 4.Which measures best predict brain atrophy? Here we show an ordered ranking of predictors of brain atrophy, divided into clinical characteristics (top), absolute values (middle) and
ratios (bottom) of brainmetabolite levels. The ranking here is based on the overall effect size, as indicated by the number of signiﬁcant voxels passing the FDR correction (percentage of the
whole brain). This method considers the ability of each measure to predict brain atrophy diffusely throughout the brain, considering both the size of the effect on brain volume, and the
proportion of the brain showing detectable associations.
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the FWM.4. Discussion
This study is the ﬁrst analysis to use TBM tomap and understand the
3D proﬁle of regional brain volume variations in a group of 210 HIV-
infected individuals on stable cART. We identiﬁed a broad range of
brain regions where the degree of volumetric atrophy was related to
metabolite levels in various key brain substructures, including the
basal ganglia, frontal white matter, and medial frontal cortex. Unlike
the traditional ROI-based approach, TBM can detect andmap the proﬁle
of diffuse white matter effects, adding a new dimension by mapping
voxel-wise white matter and subcortical volume deﬁcits along with
their associations in the context of chronic disease and cART. Our two
main ﬁndings were that (1) lower nadir CD4+ count was strongly
associated with cerebral white matter deﬁcits; and (2) disruptions
or alterations in region speciﬁc metabolites were linked to local and
widespread deﬁcits in brain volume. These results are largely in line
with expectations, with the added beneﬁt of mapping the proﬁle of
effects in 3D throughout the brain.
Nadir CD4+ count reﬂects the history of greatest immunosuppres-
sion and is a major risk factor for neurocognitive impairment in people
undergoing treatment for HIV infection. While prior studies have con-
sistently demonstrated the relationship between lower nadir CD4+
count and greater brain deﬁcits in white matter and subcortical gray
matter volumes, the correlates in the brain of other HIV clinical mea-
sures are somewhat inconsistent (Cohen et al., 2010b; Jernigan et al.,
2011; Tate et al., 2011). In our study, which is relatively well powered
given the large sample, we did not ﬁnd signiﬁcant associations between
brain volume andother clinicalmeasures. Prior reports have shown that
detectable plasmaHIVRNA, current CD4+count, duration on cART, and
ADC stage were associated with brain volume deﬁcits (Cohen et al.,
2010b; Jernigan et al., 2011; Tate et al., 2011). Findings in MRSmetabo-
lites were largely consistent with existing literature except for Glx
(Cohen et al., 2010a; Mohamed et al., 2010). These discrepancies may
be due to differences in sample size and patient inclusion criteria.
Some of the differences in the clinical correlations may be due to theimage analysis approaches (ROI based methods vs. unbiased TBM),
which will be discussed later.
In prior studies from the same consortium, absolute and relative
metabolite concentrations were associated with gray matter and ven-
tricular volumes, but not with the total white matter volume (Cohen
et al., 2010a). Lower nadir CD4+ count was associated with a lower
totalwhitematter volume, but without anatomical details on the affect-
ed regions (Cohen et al., 2010b) and with decreases in corpus callosum
areas in another HIVNC study (Tate et al., 2011). The current study iden-
tiﬁed several white matter regions where atrophy was associated with
brain metabolite levels, and with nadir CD4+ count. Glx levels mea-
sured in BG were primarily linked to frontal white matter deﬁcits and
CSF expansion (Fig. 1), while the effects of NAA measured in FWM
and nadir CD4+ count were more widespread, affecting the whole
brain white matter while showing greater associations in the frontal
lobes (Figs. 2 and 3). Additionally, a broad spectrum of metabolite dis-
turbance, including NAA in MFC, Glx in BG, Glx in MFC, Cho in MFC
and MI in MFC, was shown to correlate with volume deﬁcits in subcor-
tical structures such as thalamus, putamen, and midbrain (Table 3).
These ﬁndings were consistent with the hypothesized primary involve-
ment of the frontal–striatal networks in HIV (Dal Pan et al., 1992; Navia
et al., 1986a, 1986b; Tate et al., 2009). Our study differs in two respects
compared to the prior studies in the same cohort. First, we used a larger
sample (N = 210, compared to N = 67 in Cohen et al., 2010a and N =
82 in Cohen et al., 2010b). Assuming other factors are comparable, this
provided greater statistical power to detect subtle effects. Second, we
used a voxel-wise analysis technique that does not rely on accurate
regional segmentation of thewhitematter, allowing thedetection of dif-
fuse whitematter effects while pinpointing regions of signiﬁcance, which
was previously unobtainable with a traditional ROI-based approach.
4.1. HIV clinical characteristics and brain atrophy
4.1.1. Immunosuppression
HIV selectively infects and destroys monocytes and T helper cells
(a type of lymphocyte) that express the surface protein CD4+. The
levels of CD4+ T cells in blood are important indicators of immuno-
suppression. Some prior studies report that decline of current CD4+
T cell counts was correlated with cognitive decline, cortical gray matter
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corpus callosum volume reduction (Thompson et al., 2006), and ven-
tricular expansion (Thompson et al., 2006). Higher current CD4+
count, indicating better immune system status, was unexpectedly cor-
related with lower white matter and subcortical gray matter volumes
as well as increased CSF (Jernigan et al., 2011). The difference in the
effect of current CD4+ count is likely due to disparities in treatment
effect, duration of treatment, or neuroinﬂammatory mechanism in
response to a combination of viral infection and treatment (Jernigan
et al., 2011). In our study, we did not detect a signiﬁcant effect of current
CD4+ count on brain atrophy. Nadir CD4+ counts, the lowest CD4+
count measured after HIV infection, predict poor immune recovery
(Negredo et al., 2010), neurocognitive impairment (Ellis et al., 2011),
and white matter volume deﬁcits (Cohen et al., 2010b; Jernigan et al.,
2011; Tate et al., 2011) in patients receiving cART. Here we found that
lower nadir CD4+ T cell counts (cell counts before cART initiation),
but not current CD4+ T cell counts, were strongly linked to regional
white matter deﬁcits across the brain. We showed for the ﬁrst time a
quantitative relationship between a reduction in nadir CD4+ and its
effect on volume loss in the white matter (1–2% decrease for every 25
point reduction in nadir CD4+). To further understand the contribution
of nadir CD4+ count to brain volume, we compared its effect with the
cerebral metabolites also associated with brain loss and found that
the nadir CD4+ showed the strongest effect size. Together these ﬁnd-
ings support the predictive value of nadir CD4+ for subsequent brain
atrophy, and the potential importance of early initiation of cART in
preventing brain damage.
4.1.2. Other HIV clinical characteristics
We did not ﬁnd a signiﬁcant correlation between regional brain vol-
umes and the other clinical measures, including current CD4+ count,
ADC stage, HIV RNA concentration in plasma or CSF, duration of HIV
infection, CPE scores, and years on HAART, after controlling for demo-
graphic factors and correcting for multiple comparisons. Prior studies
have shown lower corpus callosum areas in HIV-positive subjects com-
paredwith healthy controls, but a lesser differencewas foundwhen com-
paring the symptomatic group (ADC stage ≥ 1) versus those who were
asymptomatic (ADC stage 0) or had subclinical impairments (ADC stage
0.5); no signiﬁcant differences were found in any of the corpus callosum
areas between asymptomatic subjects (ADC stage 0) and subjects with
subclinical impairment (ADC stage 0.5) (Tate et al., 2011). This suggests
that the hypothesized linear relationship between cognitive impairment
and structural brain loss might be quite weak, as cognitive decline typi-
cally lags behind structural brain impairment. Additionally, the current
study had a smaller percentage of patients with advanced ADC stage
(ADC stage ≥ 1, 14% of the cohort), in part due to the lower incidence
of cognitive impairment since the advent of cART (Ances and Ellis,
2007; McArthur et al., 2004). Even so, the unbalanced sample might
have limited the statistical power to detect the effect. Other reports
have shown that detectable plasma HIV RNA was related to less total
white matter (Jernigan et al., 2011) and abnormalities in basal ganglia
(Cohen et al., 2010b). Additionally, longer exposure to cARTwas associat-
ed with lower white matter volume (Jernigan et al., 2011).
The inclusion criteria in the current study included nadir CD4+ cell
count less than 200 cells/mm3 (mean = 61, standard deviation = 58),
while the upper range of nadir CD4+ in Jernigan et al. (2011) was
1104 cells/mm3 (mean = 190, standard deviation = 183). The differ-
ences in inclusion criteria suggest that patients in the current study
might have a history of greater immunosuppression compared to the
ones in the Jernigan study. This may account for some of the differences
in ﬁndings.
4.2. Cerebral metabolite disruptions in chronic HIV infection
Cerebral metabolite disruptions are another consequence of HIV
infection, and they typically indicate neural injury and inﬂammatoryresponses in the brain. 1H-MRS provides a sensitive and noninvasive
in vivo method to detect these changes. Before the routine use of cART,
HIV+ patients were consistently reported as showing (1) reduced
NAA (or NAA/Cr) — a marker of neuronal metabolism, (2) elevated Cho
(Cho/Cr) — a marker of cell membrane damage, or (3) elevation in MI
(MI/Cr) — a glial cell marker (Chang et al., 1999; Lopez-Villegas et al.,
1997;Meyerhoff et al., 1999; Paley et al., 1996; Salvan et al., 1997; Tracey
et al., 1996). In vivoMRS studies have consistently demonstrated cerebral
metabolite disturbance in HIV infected brains, conﬁned to the deep gray
and white matter, and correlated with the severity of neurocognitive
impairment (Budka et al., 1991; Glass et al., 1993; Navia and Rostasy,
2005; Navia et al., 1986b; Rostasy et al., 1999; Tracey et al., 1996). In
patients with chronic HIV infection on stable treatment, neural injury
and inﬂammation measured by MRS as well as cognitive impairment
persist in the setting of cART (Cysique et al., 2004; Harezlak et al.,
2011). Analyzing a similar but smaller cohort (N = 67), cerebral metab-
olite abnormalities were correlated with total gray matter but not white
matter volume (Cohen et al., 2010a). Those analyses are further enriched
in this study, where we examined brain atrophy in greater detail, using
TBM to map 3D patterns of regional (voxel-wise) brain deﬁcits in 210
patients with HIV.We further showed that when ranking themetabolite
effects alone, decreases in NAA in frontal white matter and increases
in Glx in the basal ganglia had the strongest associations with loss of
brain volume, supporting the pathogenic importance of these metabo-
lites in the regional and global structural integrity of the HIV brain.
Findings in Glx are slightly discordant with a previous MRS study in
HIV-infected individuals by Mohamed et al. (2010), which showed
lower levels of Glx and a lower Glx/Cr ratio in FWM in patients with
HIV-associated dementia. Our study showed an association between
Glx elevation in the BG and brain volume deﬁcits, with smaller effects
observed with Glxmeasured in FWM. However, this may be due to sev-
eral differences between the two studies including the scanner ﬁeld
strength (1.5 T vs. 3.0 T), inclusion criteria (no nadir CD4+ count cutoff
in Mohamed et al.), sample size (210 in this study vs. 86 patients in
Mohamed et al.) and the analysis (here, correlationswithmorphometry
and, in the other paper, Glx differences among groups). A common in-
ference from our study and that of Mohamed et al. is that the glutamate
(Glu)-glutamine (Gln) cycle is dysregulated in HIV+ cohorts. The “Glx”
signal is deﬁned as the sum of the local concentrations of glutamate
(Glu) and glutamine (Gln), so an increase in Glx may be due to one or
both of these components. The synthesis of Glu in neurons depends
on glial re-uptake, and its conversion to Gln, which then enters neurons
and is converted to Glu, in order to resume the cycle (Gruetter et al.,
2003). One interpretation of our data is that elevated levels of Glu
may lead to neuronal excitotoxicity followed by neuronal death and
decreases in NAA – a neuronal and mitochondrial marker – and tissue
loss. In support of this, a recent study has shown in a human microglia
primary culture system that infected microglia are associated with
a signiﬁcant increase in extracellular Glu. Elevated levels of the
glutamate-generating enzyme glutaminase isoform C are also found in
post-mortem brain tissue of HIV patients with dementia compared to
HIV-negative controls (Huang et al., 2011).
4.3. Absolute versus relative MRS metabolite levels
Weexamined associations of brain volumeswith two different brain
metabolites, including their absolute concentrations and ratio to levels
of Cr. Our prior analysis suggested that the absolute metabolite concen-
tration is a more robust predictor of brain changes and cognitive func-
tion, compared to the ratio (Cohen et al., 2010a). Because absolute
measures lack a reference, we used MRS phantom data as a correction,
offering a reference value. We acknowledge that the phantom correc-
tion only partially addresses the issue. Relative metabolite concentra-
tions were calculated by dividing the absolute measures by the mean
Cr level inside the same region; however, as shown here, Cr level also
varies by clinical status, and therefore it is not really an inert reference
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the absolute concentration of Cr in the MFC independently correlated
with subcortical volumes (Tables 3 and 4). We observed a contrasting
effect of Cr in MFC and FWM especially. By using Cr as the denominator
in our analyses, the correlations between brain volumes andmetabolite
levels (NAA, Glx, MI, Cho) in MFC were weakened or eradicated, while
the correlationswithGlx,MI, and Cr in FWMwere established or further
strengthened.
4.4. Clinical implications
The results in this manuscript provide further evidence of wide-
spread disturbances in neurological function in the setting of stable
disease, and offer new insights into possible dynamic relationships be-
tween metabolic and structural injury in the HIV infected brain. This
underscores the importance of monitoring neurological function in
chronically infected patients, particularly those with a history of ad-
vanced immunosuppression who appear to be at greatest risk of devel-
oping cerebral atrophy even in the setting of cART therapies. The effect
size analysis of the MRS metabolites pinpoints for the ﬁrst time the rel-
ative importance of NAA and Glx to predict brain atrophy, suggesting
that MRS derived metabolites may provide useful predictors. The com-
bination of MRS and TBM analyses provides a useful approach to inter-
rogate the extent of metabolic and structural injury and could serve as
endpoints in clinical trials with neural restorative or protective agents.
The effect size analysis of all variables showed that the nadir CD4+
count is the most effective predictor of brain atrophy. This extends
recent observations and further supports the hypothesis that early anti-
retroviral intervention may offer an effective approach to prevent or
lessen brain atrophy over time, although future prospective studies are
needed to conﬁrm this.
4.5. Areas of signiﬁcance as a measure of effect size
In this study, ‘areas of signiﬁcance’denotes a quantitativemeasure of
effect size by counting the number of voxels that passed FDR correction,
as well as a percentage of the suprathreshold voxels relative to overall
brain volume. The analyses in this manuscript are based on an unbiased
search of the brain, and so the result was not based on prior knowledge
of regions of interest or atlas information. This kind of statistical infer-
ence is currently accepted as somewhat standard in brain mapping.
The signals quantiﬁed are ﬁrst mapped across the brain and then infer-
ences are made on the proportion of the brain where statistics exceed
values that would be expected by chance under the null hypothesis.
4.6. Limitations
Although all 210 participants had MRI scan data and nadir CD+
count, there were varying degrees of missing data in clinical character-
istics (Table 1) and brain MRS measures of metabolite levels (Table 2).
Therefore, the sample sizes varied for some of the statistical tests
depending on available data. While the sample sizes did not vary a
great deal, the CSF HIV RNA sample was notably small (N = 60), so
statistical power was lower. Another limitation is that, although nadir
CD4+ demonstrated strong associations with brain volume, we did
not adjust for nadir CD4+ while performing statistical analysis using
other variables. This was difﬁcult from a practical standpoint as we did
exploratory analyses with a large number of clinical andMRSmeasures.
With fewer covariates of interest, it would be feasible to modify the
model in accordance with a prior hypothesis and explore hierarchical
relationship. A new statistical model with all covariates (clinical, MRS
and demographic factors) included will strengthen future studies. The
statistical signiﬁcance and effect sizes will be evaluated by ﬁnding
connected regions showing consistent associations with a set of covari-
ates of interest.5. Conclusion
Structural and metabolite changes along with neurocognitive im-
pairment persist in the setting of chronic HIV infection and cART treat-
ment for reasons that are not entirely clear. In this study we showed
that TBM combined with linear regression modeling offers a sensitive
and powerful in vivo measure to map brain deﬁcits in HIV infection
and to identify factors linked to alterations in brain structure. Disrup-
tions in speciﬁc brain metabolites in the basal ganglia and frontal
whitematterwere associatedwith volumetric deﬁcits in thewhitemat-
ter and deep brain nuclei. Cerebral white matter deﬁcits were strongly
linked to lower nadir CD4+ count. These studies will advance our
understanding of how metabolic and atrophic changes unfold in the
setting of chronic infection and help pinpoint the underlying factors
contributing to such changes.
Abbreviations
ADC AIDS dementia complex
cART combined antiretroviral therapies
CNS central nervous system
CPE antiretroviral CNS penetration-effectiveness scores
CSF cerebrospinal ﬂuid
HIVNC HIV Neuroimaging Consortium
MRI magnetic resonance imaging




-Glx glutamate and glutamine
-MI myo-inositol
-NAA N-acetylaspartate
1H-MRS key brain substructures:-BG right or left deep gray matter in basal ganglia
-FWMright or left mid-frontal white matter in centrum semiovale
-MFC gray matter in mid-frontal cortex
TBM tensor-based morphometry
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